MX2017011434A - Compuestos heterociclicos triciclicos sustituidos. - Google Patents

Compuestos heterociclicos triciclicos sustituidos.

Info

Publication number
MX2017011434A
MX2017011434A MX2017011434A MX2017011434A MX2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
compounds
tricyclic heterocyclic
substituted tricyclic
cr3r3
Prior art date
Application number
MX2017011434A
Other languages
English (en)
Spanish (es)
Inventor
G Murali Dhar T
Xiao Hai-Yun
Jiang Bin
Duan Jingwu
J Tebben Andrew
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2017011434A publication Critical patent/MX2017011434A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
MX2017011434A 2015-03-18 2016-03-17 Compuestos heterociclicos triciclicos sustituidos. MX2017011434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX2017011434A true MX2017011434A (es) 2018-01-25

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011434A MX2017011434A (es) 2015-03-18 2016-03-17 Compuestos heterociclicos triciclicos sustituidos.

Country Status (14)

Country Link
US (1) US10189840B2 (enExample)
EP (1) EP3271360B1 (enExample)
JP (1) JP6793657B2 (enExample)
KR (1) KR102654709B1 (enExample)
CN (1) CN107635993B (enExample)
AU (1) AU2016233288A1 (enExample)
BR (1) BR112017019773A2 (enExample)
CA (1) CA2980159A1 (enExample)
EA (1) EA032315B1 (enExample)
ES (1) ES2797805T3 (enExample)
IL (1) IL254424A0 (enExample)
MX (1) MX2017011434A (enExample)
SG (1) SG11201707469WA (enExample)
WO (1) WO2016149436A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018167176A1 (en) 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ[1,2−a]ピリジン誘導体
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
KR20100033484A (ko) * 2007-06-26 2010-03-30 사노피-아벤티스 어닐링된 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 금속 촉매된 합성
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
US9512124B2 (en) 2014-10-06 2016-12-06 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
US20180111936A1 (en) 2018-04-26
AU2016233288A1 (en) 2017-11-09
ES2797805T3 (es) 2020-12-03
KR20170129810A (ko) 2017-11-27
EA201792034A1 (ru) 2018-03-30
IL254424A0 (en) 2017-11-30
CN107635993B (zh) 2020-05-22
CN107635993A (zh) 2018-01-26
JP2018508553A (ja) 2018-03-29
WO2016149436A1 (en) 2016-09-22
CA2980159A1 (en) 2016-09-22
BR112017019773A2 (pt) 2018-05-15
US10189840B2 (en) 2019-01-29
SG11201707469WA (en) 2017-10-30
EP3271360B1 (en) 2020-04-22
EP3271360A1 (en) 2018-01-24
EA032315B1 (ru) 2019-05-31
JP6793657B2 (ja) 2020-12-02
KR102654709B1 (ko) 2024-04-03

Similar Documents

Publication Publication Date Title
MX2017011434A (es) Compuestos heterociclicos triciclicos sustituidos.
HK1252623A1 (zh) 可用作TNFα调节剂的杂环化合物
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA202091483A1 (ru) Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
MX2017011433A (es) Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
EA202091484A1 (ru) 4-азаиндольные соединения
EA201992674A1 (ru) Тиенопиридины и бензотиофены в качестве ингибиторов irak4
MX2020005873A (es) Compuestos de 6-azaindol.
MX2020005622A (es) Compuestos de indol sustituidos con arilo y heteroarilo.
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
MX2017011577A (es) Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
MY196474A (en) [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds
MY191796A (en) Heterocyclic compounds as lsd1 inhibitors
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201791293A1 (ru) Сайт-специфическое дозирование ингибитора btk
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201991029A1 (ru) Ингибиторы magl
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
MX383074B (es) Compuestos de naftiridina como inhibidores de quinasa jak
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
MX2018001032A (es) Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции